BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
66.69
+0.55 (0.83%)
Oct 6, 2026, 9:56 AM EDT - Market open
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $243.68M in the quarter ending June 30, 2026, with 120.39% growth. This brings the company's revenue in the last twelve months to $713.07M, up 202.39% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth.
Revenue (ttm)
$713.07M
Revenue Growth
+202.39%
P/S Ratio
18.13
Revenue / Employee
$710,936
Employees
1,003
Market Cap
13.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Corcept Therapeutics | 830.81M |
| Twist Bioscience | 431.80M |
BBIO News
- 2 hours ago - BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA - TheFly
- 2 hours ago - BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - GlobeNewsWire
- 17 hours ago - BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day - GlobeNewsWire
- 1 day ago - BridgeBio Pharma presents new data from interim analysis of FORTIFY study - TheFly
- 1 day ago - BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels - GlobeNewsWire
- 13 days ago - BridgeBio Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Transcripts
- 13 days ago - BridgeBio Pharma announces results from trial of tafamidis in ATTR-CM - TheFly
- 13 days ago - Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening - GlobeNewsWire